Navigation Links
An innovation star for Europe
Date:9/30/2011

In the late nineties, researchers from a promising yet volatile French SME in the medical sector decided to bet on their own horse. The seven founders teamed-up with Grard Heinrich, an experienced businessman familiar with the pharmaceutical industry and with Gemmes Ventures, an investment fund specialising in start-up support. Now venture capital firms associated to names such as Rotschild are backing CrossJect, which is awaiting favourable conditions for stock-market flotation.

A Simple idea

The product is as simple as it is daring a needle-free injection device. Though the idea has been around since at least the last century, no-one so far has managed to develop an efficient product that can inject all kind of medical molecules with the same level precision and reliability. Most importantly, the device, called Zeneo, answers a real market need. 'We did not try to reinvent the wheel with this project, nor did we come up with a new high-tech process that was not already out there,' says Patrick Alexandre, Chief Technical Officer at CrossJect 'we created a technology able to answer a simple market opportunity'. Still the young company has been prolific in patents, with 26 different innovations registered through 370 different patents worldwide.

Market projections are equally impressive: first sales are planned for 2014 and the production of needle-free injection devices could already reach 150 million units by this time, covering a fraction of the 12 billion injections given each year worldwide; many of which are administrated by the patients themselves. With a rapidly ageing population in the western world, putting welfare state budgets under pressure, the medical community sees self-injection as a safe and reliable solution, especially adapted to the treatment of chronic diseases such as hepatitis or arthritis.

The Zeneo device is also a good solution to needle-phobia, a fairly common problem, with an estimated prevalence of 15% in the general population. This often results in patients not complying with their treatment programme. But the real potential of this project lies in the fast development of medical products based on biological compounds. 'This kind of medication is not adapted to go through the digestive system and often necessitates a recurrent use, injection is then the best solution' says Heinrich, now Chief Marketing Officer of the company.

R&D meets finance

From the very beginning of the adventure, CrossJect's strategy has been to actively look for venture capital support. One of the first venture capital companies to invest in CrossJect was Paris-based Gemmes Venture. 'CrossJect is one of the very first companies we invested in, so far we have injected in it 2,5 million euro' says Philippe Monnot, CEO of Gemmes Ventures and chair of CrossJect's supervisory board. 'It was obvious to me that the simplicity of the product and the straightforward nature of the business plan have been key to attract financing '.

Another crucial factor played in the start-up's favour: time. The common delay with commercialisation of research in the biotech sector is the long period of clinical trials. CrossJect, however, is not about testing new drugs but the development of a new way to administrate them. Consequently, the duration of clinical trials is minimal compared to other products aimed at the pharmaceutical market. 'We are talking about two years of clinical trials, when usually development of product development in this field implies a 10-year trial period' says Patrick Alexandre.

Technology comes before money

'The procedure to obtain public funding through the Eurostars Programme is astonishingly simple,' says Alexandre. Moreover, Eurostars has played an essential role in counterbalancing the risk-aversion of private investors and it has also enabled CrossJect to create a real partnership with a company with skills that could not be found in France. 'Thanks to the Eurostars Programme, Hirtenberger, an Austrian company, was able to replace our previous partner, which did not have the strength to carry the production of the device on an industrial scale'.

The mechanics behind the injection system were key to the development of the product. Within a few months, Hirtenberger managed to develop a viable solution for the injection of pharmaceutical molecules, with a notable input in the pyrotechnic method used to inoculate the drug. Hirtenberger also made possible key changes in the design of the needle-free injector possible, making it a lighter, more visually-appealing and easily marketable product and thus answering to the demands of CrossJect's industrial partners and pharmaceutical clients.

'When we first started this project, people were telling us, you have money-rich competitors who have failed in developing this technology' says Monnot. However, the company's objective has always been one of a measured and cautious development, avoiding short-term investors looking for a quick resale and profit. 'Our experience tells us that putting big money on the table does not always bring a technological project to a good end.' In that sense, the Eurostars ISTAR project has been a perfect example of cautious and well-timed investment, giving a promising start-up the little push it needed to reach the market.


'/>"/>

Contact: Piotr Pogorzelski
piotr.pogorzelski@eurekanetwork.org
32-277-70979
EUREKA
Source:Eurekalert

Related medicine news :

1. OGI and MaRS Innovation invest in peptide therapeutics
2. Austen BioInnovation Institutes Accountable Care Community initiative gains national support
3. BUSM professor honored with Excellence and Innovation in Education and Training Award
4. Innovations in cardiovascular therapies and treatments will be presented at TCT 2011
5. Three senior Hebrew University faculty members receive Kaye Awards for innovations
6. QB3, Deloitte collaborate to drive California bioscience innovation
7. Innovation in science
8. Sones Innovation Award honors breast cancer vaccine research
9. Student innovation at Rensselaer Polytechnic Institute could lead to better breast cancer screening
10. ACP applauds President Obamas call for state innovation on health insurance coverage
11. How do data exclusivity periods affect pharmaceutical innovation?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National ... Science® and international water advocate, was honored by Ashram, Inc. as the world’s foremost ... who knelt on the banks of the Nile to fill their red clay pots ...
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our ... PROTECTION TO YOUR HEAD ™”. , “We are proud to introduce Meghan ... football front we have Brian Quick, wide receiver for Los Angeles who was a ...
(Date:5/26/2016)... ... 26, 2016 , ... Metcalf & Associates’ Maureen Metcalf ... experience in leading technology and human resources operations for health care, education, banking, ... be featured on Metcalf’s VoiceAmerica radio show , Innovative Leaders Driving Thriving ...
(Date:5/26/2016)... , ... May 26, 2016 , ... May 2016 – ... so central to popular cosmetic improvement efforts. Record numbers of clients now ask about ... prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... is happy to announce the launch of its brand equity product, Brandvantage. ... to reflect the dynamic landscape of modern consumer decision-making. The proprietary framework ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... New Zealand , May 24, 2016 ... and informatics solutions for the healthcare sector, has been named ... New Zealand Hi-Tech Awards 2016. Dr Bruce ... fantastic acknowledgement for our team.  It,s really good to be ... burden healthcare internationally. Our products are used in 35 countries ...
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
(Date:5/23/2016)... , May 23, 2016 ... Handling Equipment Market by Product (Wheelchair, Scooters, Medical ... (Bariatric Care, Critical Care, Wound), Accessories (Lifting, Transfer) ... to 2021", published by MarketsandMarkets, the patient handling ... Billion by 2021 at a CAGR of 10.5% ...
Breaking Medicine Technology: